Pfizer Reports Landmark Seven-Year LORBRENA Data in Advanced ALK-Positive Lung Cancer
NEW YORK | May 29, 2026 Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial, demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK | May 29, 2026 Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial, demonstrating...
